

| | |
|--|-----------------------------------|
| Subject: Medical Technology Realignment Appropriation Title: Research, Development, Test, and Evaluation, Army, 04/05 | DoD Serial Number: FY 05-37 PA |
| | Includes Transfer? No |

| | | | | | | | | |
|---|--|--------|--|--------|----------------------|--------|-----------------|--------|
| Component Serial Number: FY 05-14 PA | <i>(Amounts in Thousands of Dollars)</i> | | | | | | | |
| | Program Base Reflecting Congressional Action | | Program Previously Approved by Sec Def | | Reprogramming Action | | Revised Program | |
| Line Item | Quantity | Amount | Quantity | Amount | Quantity | Amount | Quantity | Amount |
| a | b | c | d | e | f | g | h | i |

This reprogramming action requires prior approval because it involves a congressional special interest item. This reprogramming realigns \$2.890 million appropriated for the Stable Hemostat program to other more critical medical programs within Research, Development, Test, and Evaluation, Army, 04/05, appropriation. This action reprograms funding in support of higher priority items, based on unforeseen military requirements, than that for which the funds were originally appropriated. It meets all administrative and legal requirements and none of the items have previously been denied by the Congress

| | |
|---|-------------|
| Research, Development, Test, and Evaluation, Army, 04/05 | - |
| <u>Budget Activity 2: Applied Research</u> | |
| PE 0602787A Medical Technology | |
| 180,227 | 180,103 |
| | +924 |
| | 181,027 |

Explanation: Funds will be used to support the high priority applied research efforts of Control of Insect Vector, Malaria Drug research, and Leishmaniasis applied research.

| | |
|---|-------------|
| <u>Budget Activity 3: Advanced Technology Development</u> | |
| PE 0603002A Medical Advanced Technology | |
| 220,418 | 220,266 |
| | -924 |
| | 219,342 |

Explanation: Congress appropriated \$2.890 million for Stable Hemostat in the Department of Defense Appropriations Act, 2004 (Public Law 108-87). However, the program cannot be executed as envisioned. Therefore, the funds are available to realign to fund other critical medical programs. Part of the funding (\$.924 million) will be used to support applied research efforts as described above. The balance of the special interest item (\$1.966 million) will be realigned within the Medical Advanced Technology program to fund other critical medical programs, including Leishmaniasis advanced technology research and other Combat Casualty Care research programs.

Approved (Signature and Date)
 **Tina W. Jonas** JUL 8 2005